STOCK MARKET BSE NSE

Drugmaker AstraZeneca asks US FDA to authorize COVID antibody treatment

The treatment, known as AZD7442, would be the first long-acting antibody combination to receive an emergency use authorization for COVID-19 prevention.

Published: 05th October 2021 05:47 PM  |   Last Updated: 05th October 2021 05:47 PM   |  A+A-

The AstraZeneca office building in Brussels, Friday, Jan. 29, 2021. (Photo | AP)

The AstraZeneca office building in Brussels, Friday, Jan. 29, 2021. (Photo | AP)

By PTI

LONDON: AstraZeneca, the Anglo-Swedish drugmaker that developed one of the first COVID-19 vaccines, has asked the U.S. Food and Drug Administration to authorize the emergency use of an antibody treatment to prevent the disease.

The company said Tuesday that the treatment, known as AZD7442, would be the first long-acting antibody combination to receive an emergency use authorization for COVID-19 prevention. The treatment may help protect people whose immune systems don’t respond adequately to vaccination, AstraZeneca said.

Late-stage human trials showed that AZD7442 reduced the risk of developing symptomatic COVID-19 by 77%. More than three-quarters of the participants had suppressed immune systems and other conditions that made them more susceptible to severe disease.

“Vulnerable populations such as the immunocompromised often aren’t able to mount a protective response following vaccination and continue to be at risk of developing COVID-19,” Mene Pangalos, AstraZeneca's executive vice president for pharmaceutical research, said in a statement. “With this first global regulatory filing, we are one step closer to providing an additional option to help protect against COVID-19 alongside vaccines.”

U.S. demand for antibody treatments soared over the summer, particularly in states like Florida, Louisiana and Texas, where hospitalizations among unvaccinated patients threatened to overwhelm the health care system.

The drugs are laboratory-made versions of virus-blocking antibodies that help fight off infections. The treatments help the patient by supplying concentrated doses of one or two antibodies.

The main antibody treatment being used in the U.S. is Regeneron’s dual-antibody cocktail. The FDA has also authorized the Regeneron product as protection for high-risk people against severe COVID-19.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

edexworks
flipboard facebook twitter whatsapp